Allogeneic and syngeneic cells as antigen source and their efficiency in DC-based anti-melanoma vaccination.

ADRIANA MANTEGAZZA; MAC KEON, SOLEDAD; ROSA WAINSTOK; JOSÉ MORDOH; ESTRELLA LEVY; MICHAEL MARKS; BENTIVEGNA, SOFÍA

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

A major obstacle to obtaining relevant results in cancer vaccination has been the identification of immunogenic antigens. In particular, dendritic cell (DC)-based cancer immunotherapy can be achieved by loading DCs with syngeneic or allogeneic cells, but the consequences brought upon anti-tumor protection are not clear. When using syngeneic tumor cells, tumor self-antigens are provided, including tumor-associated antigens (TAAs) and neoantigens generated through mutations during tumor progression. On the other hand, allogeneic tumor cells can supply shared TAAs and allo-MHC- I. To assess the advantages of each system, we have analyzed in a murine model the effect on anti-melanoma protection of loading DCs with irradiated syngeneic B16-F1 (H-2Kb and H-2Db haplotype), allogeneic Cloudman melanoma or allogenic 4T1 breast cancer cells (H-2Kd and H-2Dd haplotype).